Different Outcomes of Anti-VEGF Treatment for Neovascular AMD according to Neovascular Sutypes and Baseline Features: 2-Year Real-Life Clinical Outcomes

Table 4

Stratified analysis on the basis of anti-VEGF treatment. The following abbreviations are used: BCVA: best-corrected visual acuity; CMT: central macular thickness.

Stratified analysis on the basis of anti-VEGF treatment
		BCVA baseline	BCVA 1 y	BCVA 2 y	CMT baseline	CMT 1 y	CMT 2 y	N. IV 1 y	N. IV 2 y	TOT N. IV
Ranibizumab	MMean	0.47	0.41	0.45	364	329	307	5.5	2.9	8.4
	STD	0.36	0.4	0.42	125	84	63	1.7	1.8	3.2
Aflibercept	MMean	0.504	0.45	0.44	402	345	299	5.3	2.6	7.9
	STD	0.34	0.4	0.39	136	105	62	1.4	1.8	2.8
Switch	Mean	0.384	0.33	0.34	373	326	317	7.6	4.9	12.5
	STD	0.287	0.28	0.3	76	88	61	1.6	2.0	3.6